Effect of Saroglitazar on in NAFLD.

To assess the Effect of Saroglitazar on Fatty Liver Index and Fibroscan parameters [Linear Shear Measurement (LSM) and Controlled Attenuation Parameters (CAP)] in patients of Non Alcoholic Fatty Liver Disease - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085418

Enrollment

100

Registered

2025-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: DRUG SAROGLITAZAR: Effect of Saroglitazar on Fatty liver index parameters and Fibroscan parameters [LSM(Linear shear measurement) and CAP(Controlled Attenuated Parameter Intervention2:

Eligibility

Inclusion criteria

Inclusion criteria: 18–65 years diagnosed of NAFLD

Exclusion criteria

Exclusion criteria: 1.patient with cirrhosis 2. significant alcohol intake 3.use of thiazolidinediones 4.use of drugs causing hepatic fibrosis (amiodarone ,anabolic steroids ,chloroquine,estrogens,high dose vitamin a ,ocp , systemic glucocorticosteroids ) 5. liver diseases due to oter etiologies like autoimmune liver disease.

Design outcomes

Primary

Measure	Time frame
Effect of Saroglitazar on Fatty liver index parameters and Fibroscan parameters [LSM(Linear shear measurement) and CAP(Controlled Attenuated Parameter )] in Patients of Non Alcoholic Fatty liver DiseaseTimepoint: Assessed at 0 and 3 months	—

Secondary

Measure	Time frame
Effect of Saroglitazar on Fatty liver index parameters and Fibroscan parameters [LSM(Linear shear measurement) and CAP(Controlled Attenuated Parameter )] in Patients of Non Alcoholic Fatty liver DiseaseTimepoint: 3 MONTHS	—

Countries

India

Contacts

Public ContactSandeep Goyal

Pt. B.D. Sharma PGIMS, Rohtak

sandeepgoyal20000@gmail.com9968969651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026